# EDGAR Filing Document

**Accession Number:** 0001889218
**File Stem:** 0001641172-25-014097
**Filing Date:** 2025-6
**Character Count:** 7031
**Document Hash:** ca7c5d03e0c5eb5d1c09a2c41e2efd8c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-014097.hdr.sgml**: 20250606

**ACCESSION NUMBER**: 0001641172-25-014097

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250604

**FILED AS OF DATE**: 20250606

**DATE AS OF CHANGE**: 20250606

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Angle Siddhesh Rajendra
- **CENTRAL INDEX KEY:** 0001889218

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40899
- **FILM NUMBER:** 251031905

**MAIL ADDRESS:**
- **STREET 1:** 481 MONMOUTH ST, UNIT G,
- **CITY:** JERSEY CITY
- **STATE:** NJ
- **ZIP:** 07302
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bone Biologics Corp
- **CENTRAL INDEX KEY:** 0001419554
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 421743430
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2 BURLINGTON WOODS DRIVE,
- **STREET 2:** SUITE 100,
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** (781) 552-4452

**MAIL ADDRESS:**
- **STREET 1:** 2 BURLINGTON WOODS DRIVE,
- **STREET 2:** SUITE 100,
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bone Biologics, Corp.
- **DATE OF NAME CHANGE:** 20140924

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AFH ACQUISITION X, INC.
- **DATE OF NAME CHANGE:** 20071127

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Angle Siddhesh Rajendra<br><sub>(Last) (First) (Middle)</sub><br>C/O BONE BIOLOGICS CORP,<br>2 BURLINGTON WOODS DR. SUITE 100<br><sub>(Street)</sub><br>BURLINGTON,, MA 01803<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Bone Biologics Corp [ BBLG ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Non-Employee Stock Option | $0.88 | 2025-06-04 |  | A |  | 62894 |  | <sup>(1)</sup> | 2035-06-04 | Common Stock | 62894 | $0 | 62894 | D |  |
| Non-Employee Stock Option | $1.73 |  |  |  |  |  |  | <sup>(2)</sup> | 2034-09-17 | Common Stock | 30713 |  | 30713 | D |  |
| Non-Employee Stock Option | $5.12 |  |  |  |  |  |  | <sup>(3)</sup> | 2033-09-13 | Common Stock | 10721 |  | 10721 | D |  |
| Non-Employee Stock Option | $387.28 |  |  |  |  |  |  | <sup>(3)</sup> | 2027-08-23 | Common Stock | 154 |  | 154 | D |  |
| Non-Employee Stock Option | $844.80 |  |  |  |  |  |  | <sup>(3)</sup> | 2032-01-01 | Common Stock | 37 |  | 37 | D |  |
| Non-Employee Stock Option | $1260.00 |  |  |  |  |  |  | <sup>(3)</sup> | 2031-10-26 | Common Stock | 13 |  | 13 | D |  |
| Non-Employee Stock Option | $1260.00 |  |  |  |  |  |  | <sup>(3)</sup> | 2031-10-15 | Common Stock | 84 |  | 84 | D |  |

---

### Footnotes:

(1) This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

(2) This option was granted on 9/17/2024 and vests in four equal quarterly installments.

(3) This option is fully exercisable as of the date of this report.

**Signature:** /s/ Siddhesh Angle  
**Date:** 2025-06-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**